These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 8624270)
1. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group. Nakano T; Ikegami H; Nakamura S; Kawase T; Nishikawa H; Yokota S; Yoshida M; Tachibana T; Igarashi T; Komuta K; Higashino K Br J Cancer; 1996 May; 73(9):1096-100. PubMed ID: 8624270 [TBL] [Abstract][Full Text] [Related]
2. A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. Atagi S; Kawahara M; Hosoe S; Ogawara M; Kawaguchi T; Okishio K; Naka N; Sunami T; Mitsuoka S; Akira M Lung Cancer; 2002 Apr; 36(1):105-11. PubMed ID: 11891041 [TBL] [Abstract][Full Text] [Related]
3. A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer. Ellis PA; Talbot DC; Nicolson MC; Priest K; Ashley S; Smith IE Br J Cancer; 1995 Jun; 71(6):1315-8. PubMed ID: 7779730 [TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial. Vansteenkiste J; Vandebroek J; Mariën S; Roex L; Bertrand P; Bockaert J; De Beukelaar T; Deman R; De Muynck P; Ulrichts H Lung Cancer; 1995 Dec; 13(3):295-303. PubMed ID: 8719069 [TBL] [Abstract][Full Text] [Related]
5. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015 [TBL] [Abstract][Full Text] [Related]
6. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Cardenal F; Domine M; Massutí B; Carrato A; Felip E; Garrido P; Juan O; Artal A; Barneto I; López-Vivanco G; Balcells M; Rosell R Lung Cancer; 2003 Feb; 39(2):201-7. PubMed ID: 12581574 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study. Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer. Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B. Richards F; Perry DJ; Goutsou M; Modeas C; Muchmore E; Rege V; Chahinian AP; Hirsh V; Poiesz B; Green MR Cancer; 1991 Jun; 67(12):2974-9. PubMed ID: 1646066 [TBL] [Abstract][Full Text] [Related]
11. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. Souquet PJ; Krzakowski M; Ramlau R; Sun XS; Lopez-Vivanco G; Puozzo C; Pouget JC; Pinel MC; Rosell R Clin Lung Cancer; 2010 Mar; 11(2):105-13. PubMed ID: 20199976 [TBL] [Abstract][Full Text] [Related]
12. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490 [TBL] [Abstract][Full Text] [Related]
13. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA; Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340 [TBL] [Abstract][Full Text] [Related]
14. [An early phase II trial combining cisplatin, carboplatin and vindesine in patients with inoperable non-small cell lung cancer]. Haneda H; Koizumi M; Hayashi T Gan To Kagaku Ryoho; 2000 Feb; 27(2):227-31. PubMed ID: 10700892 [TBL] [Abstract][Full Text] [Related]
15. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study. Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234 [TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
17. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Rixe O; Gatineau M; Jauffret E; Spano JP; Orcel B; Vannetzel JM; Berille J; Derenne JP; Khayat D Bull Cancer; 2005 Jan; 92(1):E1-6. PubMed ID: 15689321 [TBL] [Abstract][Full Text] [Related]
18. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer. Klastersky J; Sculier JP; Ries F; Dabouis G; Libert P; Schmerber J; Thiriaux J; Berchier MC; Bureau G; Van Cutsem O Lung Cancer; 1994 Dec; 11(5-6):373-84. PubMed ID: 7704494 [TBL] [Abstract][Full Text] [Related]
19. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]. Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091 [TBL] [Abstract][Full Text] [Related]
20. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N; Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]